NEW YORK, NY / ACCESS Newswire / July 30, 2025 / If you suffered a loss on your Vestis Corporation (NYSE:VSTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/vestis-corporation-lawsuit-submission-form?prid=158772&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

LUXEMBOURG, July 30, 2025 (GLOBE NEWSWIRE) — Bitcoin Swift (BTC3) a next-generation decentralized financial protocol, has officially entered Stage 2 of its limited 64-day presale, offering early access to its programmable staking rewards and upcoming governance framework powered by artificial intelligence. The presale is scheduled to conclude on September 18, 2025, with Stage 3 pricing

Fannie Mae (OTCQB: FNMA) today reported its second quarter 2025 financial results and filed its Second Quarter 2025 Form 10-Q with the Securities and Exchange Commission. The filing provides condensed consolidated financial statements for the quarter ended June 30, 2025. The following documents are now available on Fannie Mae's website at www.fanniemae.com. https://mma.prnewswire.com/media/1608392/Fannie_Mae_Logo.jpg — Press

Bitcoin Swift Announces Stage 2 Presale and AI-Driven Governance Rollout Ahead of 2026 Ecosystem Launch GlobeNewswire July 30, 2025 LUXEMBOURG, July 30, 2025 (GLOBE NEWSWIRE) — Bitcoin Swift (BTC3) a next-generation decentralized financial protocol, has officially entered Stage 2 of its limited 64-day presale, offering early access to its programmable staking rewards and upcoming governance

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / If you suffered a loss on your Hims & Hers Health, Inc. (NYSE:HIMS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/hims-hers-health-inc-lawsuit-submission-form?prid=158779&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. via email at

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases MIAMI, FLORIDA / ACCESS Newswire / July 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / If you suffered a loss on your 3D Systems Corporation (NYSE:DDD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/3d-systems-corporation-lawsuit-submission-form?prid=158780&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

(CNSX:ROBO),(Boerse Frankfurt – Freiverkehr:0XM1),(Pinksheets:TRMNF),(PinkSheets:TRMNF),(Pinksheets:RBOHF),(PinkSheets:RBOHF), Vancouver, BC, July 30, 2025 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCPK:RBOHF), a publicly traded investment issuer focused on the humanoid robotics and embodied AI sector, is pleased to announce that Dr. Yue Hu is the first to formally join its newly formed

(CNSX:NXT.CN),(Boerse Frankfurt – Freiverkehr:Z12),(OTC US:NXTDF),(OTCQB:NXTDF), Vancouver, BC, July 30, 2025 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company“) is pleased to announce its planned strategic integration with the Bittensor (TAO) ecosystem, a decentralized network designed for AI model training and machine intelligence validation. Subject to the receipt of all

(NasdaqGM:WVE), WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single